Hims & Hers enters weight loss market with potential game-changing injections

From Nasdaq: 2024-05-28 12:33:00

In a podcast, Motley Fool analysts discuss Hims & Hers entering the GLP-1 weight loss market, impacting companies like Novo Nordisk and Eli Lilly. Wix’s pivot to free-cash-flow boosts from AI is highlighted. Motley Fool analysts also analyze why gym stocks haven’t performed well recently. Hims & Hers’ expansion into weight-loss injections is seen as a potential game-changer, offering a low-cost alternative to name-brand drugs. The company’s combined telehealth and pharmacy model raises some concerns about being both the doctor and medication provider. Despite risks, the company’s personalized approach to difficult health topics like weight loss and sexual health could drive growth.



Read more at Nasdaq: A New Name in Weight Loss Drugs